All nations are united in their desire to protect the most at risk in their community.

We know that COVID-19 infection continues to disproportionately impact the immunosuppressed. However, disagreement in the way we define and subdivide this clinical risk group affects our ability to monitor their infection outcomes with precision or allocate medical supervision and supplies based on need. Often, these patients are treated as a single-entity, potentially erasing sub-trends of urgent clinical importance in the process.

By this study’s end, The DESTINIES Consortium will surface an internationally aligned and risk-stratified definition of immunosuppression. Such an offering has significant value for clinical decision-making. Once integrated into disease surveillance data flows, this work can deliver the high-resolution intelligence that is needed to target care for the immunosuppressed.